Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10653662 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
US9486437 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
US9861607 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
US10238620 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
US10653660 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
US11110074 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
US9572814 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
US7915307 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Aug, 2027
(3 years from now) | |
US11234954 | CURRAX | Low-dose doxepin for treatment of sleep disorders in elderly patients |
Jan, 2028
(4 years from now) | |
US9907780 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(4 years from now) | |
US10548871 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(4 years from now) | |
US11096920 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(4 years from now) | |
US9107898 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2028
(4 years from now) | |
US9532971 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Jun, 2029
(5 years from now) | |
US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(6 years from now) |
Silenor is owned by Currax.
Silenor contains Doxepin Hydrochloride.
Silenor has a total of 15 drug patents out of which 0 drug patents have expired.
Silenor was authorised for market use on 17 March, 2010.
Silenor is available in tablet;oral dosage forms.
Silenor can be used as treatment of insomnia.
The generics of Silenor are possible to be released after 07 September, 2030.
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic